Clinical Trial

18F-Fluciclovine PET-MRI in High-grade Glioma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-09-21; most recent amendment 2025-12-03.
Status change: Not Yet Recruiting → Recruiting 2022-12-22
Trial Details
NCT Number NCT05553041
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: Blue Earth Diagnostics, Dragon Master Foundation
Conditions Glioma, High Grade Glioma, Glioma, Malignant, Glioma Intracranial, Diffuse Glioma
Enrollment 30 participants
Start Date 2024-08-07
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-04